HIV and prostate cancer

Matthew S. Wosnitzer, Jennifer J. Ahn, Franklin C. Lowe

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Highly active antiretroviral therapy (HAART) for the treatment of HIV-positive patients has delayed progression of HIV to AIDS and promoted immune system restoration thereby reducing AIDS-related mortality. Non-AIDS-defining malignancies such as prostate cancer (PCa) have been diagnosed more frequently given such extended survival. However, the actual incidence of prostate cancer in the HIV population remains ambiguous. This chapter includes search of all English-language articles describing HIV and prostate cancer between 1975 and 2011. A total of 1,178 patients with HIV and PCa were identified from the literature (87 patients from case reports, 1,091 from population-based studies). Prostate cancer incidence in HIV patients is different than the general population in multiple studies, and in the largest and most recent PSA-era population studies, incidence is typically decreased compared with the general population. During the HAART era, differences in PSA kinetics and prostate cancer behavior between HIV-positive and HIV-negative patients have not been apparent. HIV-infected patients should be managed in accordance with the most recent American Urological Association (AUA) guidelines which recommend screening of all men with age ≥40 years and a life expectancy of >10 years. All treatment options offered to the general population with prostate cancer should be available to the HIV-positive population with prostate cancer. Although long-term outcomes are still being accrued, initial results indicate response rates which are similar to HIV-negative patients.

Original languageEnglish (US)
Title of host publicationProstate Cancer: A Comprehensive Perspective
PublisherSpringer-Verlag London Ltd
Pages123-134
Number of pages12
ISBN (Print)9781447128649, 144712863X, 9781447128632
DOIs
StatePublished - Jul 1 2013
Externally publishedYes

Fingerprint

Prostatic Neoplasms
HIV
Population
Highly Active Antiretroviral Therapy
Acquired Immunodeficiency Syndrome
Incidence
Life Expectancy
Immune System
Cohort Studies
Language
Guidelines
Survival
Mortality
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Wosnitzer, M. S., Ahn, J. J., & Lowe, F. C. (2013). HIV and prostate cancer. In Prostate Cancer: A Comprehensive Perspective (pp. 123-134). Springer-Verlag London Ltd. https://doi.org/10.1007/978-1-4471-2864-9_10

HIV and prostate cancer. / Wosnitzer, Matthew S.; Ahn, Jennifer J.; Lowe, Franklin C.

Prostate Cancer: A Comprehensive Perspective. Springer-Verlag London Ltd, 2013. p. 123-134.

Research output: Chapter in Book/Report/Conference proceedingChapter

Wosnitzer, MS, Ahn, JJ & Lowe, FC 2013, HIV and prostate cancer. in Prostate Cancer: A Comprehensive Perspective. Springer-Verlag London Ltd, pp. 123-134. https://doi.org/10.1007/978-1-4471-2864-9_10
Wosnitzer MS, Ahn JJ, Lowe FC. HIV and prostate cancer. In Prostate Cancer: A Comprehensive Perspective. Springer-Verlag London Ltd. 2013. p. 123-134 https://doi.org/10.1007/978-1-4471-2864-9_10
Wosnitzer, Matthew S. ; Ahn, Jennifer J. ; Lowe, Franklin C. / HIV and prostate cancer. Prostate Cancer: A Comprehensive Perspective. Springer-Verlag London Ltd, 2013. pp. 123-134
@inbook{998d01fe64404315aaf743341a87923b,
title = "HIV and prostate cancer",
abstract = "Highly active antiretroviral therapy (HAART) for the treatment of HIV-positive patients has delayed progression of HIV to AIDS and promoted immune system restoration thereby reducing AIDS-related mortality. Non-AIDS-defining malignancies such as prostate cancer (PCa) have been diagnosed more frequently given such extended survival. However, the actual incidence of prostate cancer in the HIV population remains ambiguous. This chapter includes search of all English-language articles describing HIV and prostate cancer between 1975 and 2011. A total of 1,178 patients with HIV and PCa were identified from the literature (87 patients from case reports, 1,091 from population-based studies). Prostate cancer incidence in HIV patients is different than the general population in multiple studies, and in the largest and most recent PSA-era population studies, incidence is typically decreased compared with the general population. During the HAART era, differences in PSA kinetics and prostate cancer behavior between HIV-positive and HIV-negative patients have not been apparent. HIV-infected patients should be managed in accordance with the most recent American Urological Association (AUA) guidelines which recommend screening of all men with age ≥40 years and a life expectancy of >10 years. All treatment options offered to the general population with prostate cancer should be available to the HIV-positive population with prostate cancer. Although long-term outcomes are still being accrued, initial results indicate response rates which are similar to HIV-negative patients.",
author = "Wosnitzer, {Matthew S.} and Ahn, {Jennifer J.} and Lowe, {Franklin C.}",
year = "2013",
month = "7",
day = "1",
doi = "10.1007/978-1-4471-2864-9_10",
language = "English (US)",
isbn = "9781447128649",
pages = "123--134",
booktitle = "Prostate Cancer: A Comprehensive Perspective",
publisher = "Springer-Verlag London Ltd",

}

TY - CHAP

T1 - HIV and prostate cancer

AU - Wosnitzer, Matthew S.

AU - Ahn, Jennifer J.

AU - Lowe, Franklin C.

PY - 2013/7/1

Y1 - 2013/7/1

N2 - Highly active antiretroviral therapy (HAART) for the treatment of HIV-positive patients has delayed progression of HIV to AIDS and promoted immune system restoration thereby reducing AIDS-related mortality. Non-AIDS-defining malignancies such as prostate cancer (PCa) have been diagnosed more frequently given such extended survival. However, the actual incidence of prostate cancer in the HIV population remains ambiguous. This chapter includes search of all English-language articles describing HIV and prostate cancer between 1975 and 2011. A total of 1,178 patients with HIV and PCa were identified from the literature (87 patients from case reports, 1,091 from population-based studies). Prostate cancer incidence in HIV patients is different than the general population in multiple studies, and in the largest and most recent PSA-era population studies, incidence is typically decreased compared with the general population. During the HAART era, differences in PSA kinetics and prostate cancer behavior between HIV-positive and HIV-negative patients have not been apparent. HIV-infected patients should be managed in accordance with the most recent American Urological Association (AUA) guidelines which recommend screening of all men with age ≥40 years and a life expectancy of >10 years. All treatment options offered to the general population with prostate cancer should be available to the HIV-positive population with prostate cancer. Although long-term outcomes are still being accrued, initial results indicate response rates which are similar to HIV-negative patients.

AB - Highly active antiretroviral therapy (HAART) for the treatment of HIV-positive patients has delayed progression of HIV to AIDS and promoted immune system restoration thereby reducing AIDS-related mortality. Non-AIDS-defining malignancies such as prostate cancer (PCa) have been diagnosed more frequently given such extended survival. However, the actual incidence of prostate cancer in the HIV population remains ambiguous. This chapter includes search of all English-language articles describing HIV and prostate cancer between 1975 and 2011. A total of 1,178 patients with HIV and PCa were identified from the literature (87 patients from case reports, 1,091 from population-based studies). Prostate cancer incidence in HIV patients is different than the general population in multiple studies, and in the largest and most recent PSA-era population studies, incidence is typically decreased compared with the general population. During the HAART era, differences in PSA kinetics and prostate cancer behavior between HIV-positive and HIV-negative patients have not been apparent. HIV-infected patients should be managed in accordance with the most recent American Urological Association (AUA) guidelines which recommend screening of all men with age ≥40 years and a life expectancy of >10 years. All treatment options offered to the general population with prostate cancer should be available to the HIV-positive population with prostate cancer. Although long-term outcomes are still being accrued, initial results indicate response rates which are similar to HIV-negative patients.

UR - http://www.scopus.com/inward/record.url?scp=84929045941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929045941&partnerID=8YFLogxK

U2 - 10.1007/978-1-4471-2864-9_10

DO - 10.1007/978-1-4471-2864-9_10

M3 - Chapter

SN - 9781447128649

SN - 144712863X

SN - 9781447128632

SP - 123

EP - 134

BT - Prostate Cancer: A Comprehensive Perspective

PB - Springer-Verlag London Ltd

ER -